AQR Capital Management LLC trimmed its holdings in Savara Inc (NASDAQ:SVRA – Free Report) by 22.2% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 16,483 shares of the company’s stock after selling 4,709 shares during the period. AQR Capital Management LLC’s holdings in Savara were worth $66,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors have also recently added to or reduced their stakes in the business. CANADA LIFE ASSURANCE Co acquired a new stake in shares of Savara during the 1st quarter worth about $35,000. Choreo LLC acquired a new stake in shares of Savara during the 2nd quarter worth about $59,000. DRW Securities LLC acquired a new stake in shares of Savara during the 2nd quarter worth about $62,000. Principal Financial Group Inc. boosted its stake in shares of Savara by 64.4% during the 2nd quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock worth $72,000 after purchasing an additional 6,973 shares during the last quarter. Finally, Profund Advisors LLC acquired a new stake in shares of Savara during the 2nd quarter worth about $105,000. 87.93% of the stock is owned by institutional investors and hedge funds.
Savara Stock Performance
Savara stock opened at $3.76 on Friday. The company has a market cap of $519.59 million, a PE ratio of -10.16 and a beta of 0.96. The company has a fifty day moving average price of $4.18 and a two-hundred day moving average price of $4.36. The company has a debt-to-equity ratio of 0.26, a current ratio of 11.31 and a quick ratio of 11.31. Savara Inc has a 12 month low of $3.12 and a 12 month high of $5.70.
Wall Street Analyst Weigh In
SVRA has been the topic of several research analyst reports. JMP Securities reissued a “market outperform” rating and issued a $9.00 target price on shares of Savara in a research report on Tuesday, October 1st. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Savara in a report on Tuesday, October 8th. Oppenheimer raised their price target on shares of Savara from $11.00 to $15.00 and gave the company an “outperform” rating in a report on Wednesday, June 26th. Finally, Guggenheim raised their price target on shares of Savara from $8.00 to $10.00 and gave the company a “buy” rating in a report on Thursday, June 27th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $11.17.
Check Out Our Latest Stock Analysis on Savara
Savara Profile
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Read More
- Five stocks we like better than Savara
- Why Invest in 5G? How to Invest in 5G Stocks
- Survey Reveals: America’s Most Coveted Businesses in 2024
- What Is WallStreetBets and What Stocks Are They Targeting?
- Top 3 Stocks to Play Oil’s Potential Comeback Rally
- How to Use the MarketBeat Excel Dividend Calculator
- Analysts See Growth in CrowdStrike Stock Despite July Setback
Want to see what other hedge funds are holding SVRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Savara Inc (NASDAQ:SVRA – Free Report).
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.